Close Menu

NEW YORK – Chinese molecular diagnostics firm Burning Rock Biotech announced Sunday a strategic collaboration with CStone Pharmaceuticals to co-develop and commercialize companion diagnostics for Blueprint Medicines' pralsetinib in China.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.